Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05754255
Other study ID # 17675
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date September 2023
Est. completion date June 3, 2024

Study information

Verified date January 2024
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the prospective study is to compare the incidence, duration, and severity of oxygen desaturation in high-risk patients randomized to nasal mask with nasal positive airway pressure (PAP) or standard care (nasal cannula) receiving propofol sedation during colonoscopy in an ambulatory surgical center (ASC). Patients will be randomized in groups of ten to one of two groups using a random number table. Group A: standard care with a nasal cannula. Group B: SuperNO2VA™EtCO2. Following the procedure subjects will be asked to complete satisfaction surveys before leaving the ASC and 48 +/- hours following their procedure. Researchers will compare levels of satisfaction and levels of oxygen saturation.


Description:

This study involves the oxygenation, continuous positive airway pressure, and ventilation of a subject via nasal mask and oxygenation via a closed facemask. The interventions directly related to this study are that of supplement oxygen, bag-mask ventilation, and continuous nasal CPAP intra-operatively and in the recovery unit. Patients will be randomized in groups of ten to one of two groups using a random number table. Group A: standard care with a nasal cannula. Group B: SuperNO2VA™EtCO2. For each anesthetic case, a preoperative history and physical and intraoperative record will be documented. Once in the endoscopy suite, the patients will have baseline vital signs, EtCO2 and oxygen levels measured. Continuous monitoring of heart rate, end tidal CO2 (EtC02), O2 saturation, and every 3-minutes BP monitoring will be obtained. For patients randomized to group A, the anesthesia provider will supply oxygen via nasal cannula at 10LPM. For patients randomized to group B, the anesthesia provider will attach the SuperNO2VA™ EtCO2's circuit port to the hyperinflation bag with the oxygen flow rate to 10 L/min, and the adjustable pressure-limiting (APL) valve completely closed. Initial propofol bolus of 0.5-1.0 mg/kg actual body weight will be administered for sedation. No other sedative or analgesic will be permitted besides propofol. MOAA/S scores will be assessed by the anesthesiologist and medical team and recorded by the research assistant. If the patient's MOAA/S score is ≥ 4, additional 20-50 mg boluses will be administered every 30 - 90 seconds until a MOAA/S score <4 is reached. Once a MOAA/S <4 is reached the endoscopist will insert the colonoscope into the rectum. Sedation will be titrated to maintain a MOAA/S <4 throughout the procedure. If the patient's MOAA/S score ≥4, additional 20-50 mg boluses of propofol will be administered every 30-90 seconds until the MOAA/S is <4. The measurements recorded during colonoscopy for both groups will be: time of administration of sedation; incidence, severity, and duration of oxygen desaturation; number, duration and reason for performing the airway maneuver(s); duration of the procedure; total dose of medication; blood pressure, heart and respiratory rate, and oxygen saturation; time to full recovery; and patient cooperation. The research assistant will document their patient's depth of sedation, cooperation with procedure, and safety. Endoscope techniques performed during the procedure such as biopsies, dilation, polypectomy, etc. will be tracked. Techniques to facilitate proximal passage of the endoscope such as moving the patient or abdominal pressure will also be noted. If the anatomic extent desired to complete the colonoscopy is not reached (i.e., colon stricture, excessive looping of the instrument), then the patient will be withdrawn from the study. Patients will recover in the endoscopy suite. The patients will have continuous monitoring of heart rate, end tidal CO2 (EtC02), O2 saturation, and every 5-minute BP monitoring and MOAAS Score. Once a MOAAS score of 5 is obtained, the patient will be offered to drink independently unless deemed inappropriate by the treating physician(s). The endoscopist when available will discuss findings with the patient and/or family, the patient will then dress and leave the endoscopy suite when possible. The time to discharge will be obtained for each patient. Patients will also complete a satisfaction and pain questionnaire before discharge. Subjects will be sent surveys to complete at 48 hours post discharge, concerning their satisfaction and their subjective degree of impairment due to the sedation. They will have the option to complete this electronically via a link to REDCap or with a self-addressed envelope and paper form of the survey. If the patients do not complete or send back their questionnaire, someone will contact them by telephone to collect the data. A statistician using student T-test, Fishers exact test, and other statistical methods they deem appropriate will analyze the collected data.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 3, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years 2. Outpatients undergoing colonoscopy. 3. American Society of Anesthesiology (ASA) Physical Status I-III 4. BMI =35 kg/m2, documented obstructive sleep apnea or BMI>30 with STOP-BANG score =3 5. Written informed consent Exclusion Criteria: 1. Inpatient status 2. Active Congestive Heart Failure Exacerbation 3. Untreated ischemic heart disease 4. Acute exacerbation of respiratory disorders, including COPD and asthma 5. Emergent procedures 6. Pregnancy 7. Previous enrollment in this study 8. Inability to provide informed consent. 9. Additional medical testing planned for the same day. 10. History of allergic reaction to propofol 11. History of allergic reaction to polypropylene or PVC. 12. Tracheostomy 13. Supra-glottic or sub-glottic tumor 14. Gastrointestinal tract obstruction or delayed transit (including delayed gastric emptying, gastric bezoar, achalasia, toxic megacolon). 15. Known obstructing colon tumor, lesion, or stricture 16. Previous colon surgery (excluding anal surgery) 17. Active GI bleeding (hematochezia or melena during procedure preparation) 18. Large polyp (> 2cm) removal 19. Previous failed or unsuccessfully completed colonoscopy.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Nasal Cannula
A nasal cannula is a medical device to provide supplemental oxygen therapy to people who have lower oxygen levels. There are two types of nasal cannulas: low flow and high flow. The device has two prongs and sits below the nose. The two prongs deliver oxygen directly into your nostrils.
Nasal Positive Airway Pressure System
Positive airway pressure (PAP) treatment uses a machine to pump air under pressure into the airway of the lungs. This helps keep the windpipe open during sleep. The forced air delivered by CPAP (continuous positive airway pressure) prevents episodes of airway collapse that block the breathing in people with obstructive sleep apnea and other breathing problems.

Locations

Country Name City State
United States Indiana University Indianapolis Indiana

Sponsors (1)

Lead Sponsor Collaborator
Indiana University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of desaturation Compare incidence of desaturation of Nasal PAP Versus Nasal Administration of Oxygen 60 minutes
Primary Duration of oxygen desaturation Compare the duration of desaturation of Nasal PAP Versus Nasal Administration of Oxygen 60 minutes
Primary Severity of oxygen desaturation Compare the severity of desaturation of Nasal PAP Versus Nasal Administration of Oxygen 60 minutes
Secondary Total Amount of Propofol for Adequate Sedation Compares amounts of Propofol for induction and entire procedure administered for procedure 60 minutes
Secondary Modified Observer's Assessment of Alertness/Sedation Scale Compare Modified Observer's Assessment of Alertness/Sedation Scale (MOAAS) scores immediately prior to endoscope insertion and during the procedure.
MOAAS scale is 0-5, where 0=No response after painful stimuli and 5 Responds to name spoken in normal tone. Patients with a MOAAS <4 are considered to be moderately to deeply sedated. The greater the degree of sedation the greater the degree of respiratory depression.
60 minutes
Secondary Endoscope Insertion Compare the length of time from induction to endoscope insertion. 60 minutes
Secondary Incidence of Airway maneuvers Compare the number of incidence of airway maneuvers 60 minutes
Secondary Duration of Airway maneuvers Compare the duration for airway maneuvers 60 minutes
Secondary Patient Satisfaction Compare patient satisfaction scores (visual analog scale (VAS)) immediately after procedure.
VAS range is from 0= Not at all satisfied to 5=Completely satisfied.
48 hours
Secondary Reason(s) for airway maneuvers Compare reason(s) for airway maneuvers as reported by anesthesiologist via open ended interview in real time. 60 minutes
Secondary Incidence of any desaturation Compare the incidence of any oxygen desaturation <85% between the start and end of sedation. 60 Minutes
Secondary Frequency of Oxygen Saturation Compare the frequency of oxygen saturation saturation <85% over 15 seconds between the start and end of sedation. 60 minutes
Secondary Frequency of bradycardia Compare the frequency of bradycardia (HR<45 bpm)between the start and end of sedation. 60 minutes
Secondary Frequency of low respiratory rate Compare the frequency of low respiratory rate (<6 per minute between the start and end of sedation. 60 minutes
Secondary Use of endotracheal intubation Compare the use of endotracheal intubation as airway management in patient population. 60 minutes
Secondary Use of Noninvasive positive pressure ventilation Compare the use of noninvasive positive pressure ventilation as airway management in patient population during sedation. 60 minutes.
Secondary Use of pharmacological blood pressure support Compare the use of pharmacological blood pressure support from the start and end of sedation. 60 minutes.
Secondary Incidence of hospitilization Compare the incidence of hospitalization following sedation for a colonoscopy in patient population. 48 hours
Secondary Serious Adverse Events Compare incidence of adverse events from start of sedation to 48 hours following the end of sedation. 48 hours
Secondary Frequency of Procedural Interruption Compare the frequency of the removal of endoscope due to a respiratory complication from start to end of sedation. 60 minutes
Secondary Duration of Procedural Interruption Compare the duration of endoscope removal due to a respiratory complication from start of sedation to end of sedation. 60 minutes.
Secondary Length of Procedure Compare the length of time for procedure from start of sedation to end of sedation. 60 minutes
Secondary Ready to discharge Compare the length of time from end of sedation to ready to discharge 30 min
Secondary Time to discharge Compare the length of time from end of sedation to actual discharge. 90 minutes
See also
  Status Clinical Trial Phase
Completed NCT04101097 - Training and Validation of Models of Factors to Predict Inadequate Bowel Preparation Colonoscopy
Completed NCT03247595 - Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy N/A
Completed NCT04214301 - An Open-Label Preference Evaluation of BLI800 Phase 4
Recruiting NCT02484105 - Comforting Conversation During Colonoscopy: A Trial on Patient Satisfaction Phase 4
Active, not recruiting NCT02264249 - Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation N/A
Terminated NCT01978509 - The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies N/A
Completed NCT01964417 - The Comparative Study Between Bowel Preparation Method Phase 3
Recruiting NCT01685970 - Comparison of Same-day 2 Sachets Picosulfate Versus High Volume PEG for Afternoon Colonoscopy Phase 3
Completed NCT01518790 - Short Course, Single-dose PEG 3350 for Colonoscopy Prep in Children N/A
Recruiting NCT00748293 - Achievement of Better Examinee Compliance on Colon Cleansing Using Commercialized Low-Residue Diet N/A
Completed NCT00779649 - MoviPrep® Versus HalfLytely®, Low-VolUme PEG Solutions for Colon Cleansing: An InvesTigator-blindEd, Randomized, Trial Phase 4
Completed NCT00671177 - Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique N/A
Completed NCT00380497 - Pico-Salax Versus Poly-Ethylene Glycol for Bowel Cleanout Before Colonoscopy in Children Phase 4
Recruiting NCT00160823 - Impact of a Self-Administered Information Leaflet on Adequacy of Colonic Cleansing for in-Hospital Patients Phase 3
Completed NCT00314418 - Patient Position and Impact on Colonoscopy Time N/A
Completed NCT00390598 - PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy Phase 2/Phase 3
Completed NCT00209573 - A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Elective Colonoscopy Phase 3
Completed NCT00427089 - Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening Phase 3
Completed NCT05823350 - The Effect of Abdominal Massage on Pain and Distention After Colonoscopy N/A
Completed NCT05397158 - Optimization of Intestinal Preparation in Older Patients N/A